BioSpace News Archive

Imbio, a healthcare technology company developing the leading suite of medical image analysis for pulmonary and cardiothoracic diseases, announced today that their FDA-cleared solutions will be available on the Nuance AI Marketplace,

Data Focused on Biomarkers of Neuroinflammation will be Topic of Key Opinion Leaders Call Set for July 14 at 8:00 AM Eastern Time

The conference will take place virtually in conjunction with the eighth NASP Annual Meeting & Expo Virtual Experience

JS InnoPharm Ltd today announced the enrollment of the first patient in a Phase 1, open-label, monotherapy dose-escalation and expansion study of JSI-1187, the company’s lead investigational drug candidate targeting the enzymes ERK1 and ERK2. The study is being conducted at 4 NCI-designated Comprehensive Cancer Centers in the U.S. JS InnoPharm holds the U.S. IND for JSI-1187, and this trial is being managed by Strate

Medtronic plc (NYSE:MDT) and Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential

Designed to enhance bone growth and help achieve fusion in surgeries involving the skeletal system Recent study shows posterolateral fusion success associated with improved patient outcomes, including reduced pain from baseline New configurations give surgeons versatile options that are easy to mold DEERFIELD, Ill.--( BUSINESS WIRE )-- Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today

Majority of the Board Members Failed to Gain Support of Majority of the Outstanding Shares Shareholders Also Rejected Company’s Executive Compensation, Stock Incentive Plan and Anti-Shareholder Rights Proposals Volition Board and Management Must Heed this Clear Mandate for Change and Commit to Delivering Tangible Results on Specific Timelines Cotterford Will Continue to Closely Monitor Progress and Take Additional Steps as Needed to Ensure

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased revenue estimate for Q2 and the full-year 2020.

Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund [www.AMRactionfund.com], a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030.

Biorasi , a leading global full-service contract research organization (CRO), has announced the start of the company’s third COVID-19 clinical trial for 2020. Taking place across the United States and Europe, the goal of the study is to evaluate the efficacy and safety of the candidate drug as an antiviral agent in hospitalized patients diagnosed with COVID-19 infections. “We are proud to have been selected as the CRO partner